Prenatal Hemophilia A Common Mutation Screening Factor VIII Intron 22 and Intron 1 Inversion Analysis
Introduction
The Prenatal Hemophilia A Common Mutation Screening is a vital genetic test designed to identify potential mutations associated with Hemophilia A, a bleeding disorder that can be inherited from parents to children. This test is particularly important for expecting parents with a family history of hemophilia, as it provides crucial insights into the health of the unborn child.
What the Test Measures
This test specifically measures mutations in the Factor VIII gene, focusing on Intron 22 and Intron 1 inversions. These mutations are known to significantly increase the risk of hemophilia A, which can lead to serious health complications if not detected early.
Who Should Consider This Test
Expectant parents, particularly those with:
- A family history of hemophilia or bleeding disorders
- Known carriers of hemophilia genes
- Concerns regarding genetic health risks for their unborn child
Benefits of Taking the Test
- Early detection of potential genetic disorders
- Informed decision-making regarding pregnancy and delivery options
- Peace of mind for expecting parents
Understanding Your Results
Results from this test will indicate whether any mutations are present. A positive result may prompt further testing or consultations with genetic counselors to discuss potential implications and management strategies.
Test Pricing
| Discount Price | Regular Price |
|---|---|
| 300,000 NGN | 400,000 NGN |
Booking Your Test
To schedule your Prenatal Hemophilia A Common Mutation Screening, please ensure you have a doctor’s prescription, as it is required for the test. This test can be conducted using various sample types including peripheral blood, amniotic fluid, chorionic villi, or cord blood.
For more information or to book your test, contact us at +2348077798758 or click the link below to secure your appointment today!
